Preparation of 2-amino-4-[(4-fluorobenzyl)amino]-1-nitrobenzene_Kain Industrial Additive

Background and overview[1] 2-Amino-4-[(4-fluorobenzyl)amino]-1-nitrobenzene can be used as a pharmaceutical synthesis intermediate. For example, retigabine is prepared, which is an anti-epileptic drug with multiple mechanisms such as a neuronal potassium channel opener and a GABA enhancer. The drug was developed by GlaxoSmithKline/Valeant Pharmaceuticals. It was approved for marketing in the EU on March 29, 2011…